Accueil   Diary - News   All news IXALTIS starts first clinical trial of Litoxetine in USA

IXALTIS starts first clinical trial of Litoxetine in USA

 

 

Toulouse (31) / Archamps (74), April 9th, 2018 -  Following the acceptance by the Food and Drug Administration of its Investigational New Drug (IND) application for Litoxetine in September 2017, Ixaltis is now launching its first clinical trial in the US.
 


This double blind randomized placebo-controlled study will explore the safety, tolerability and efficacy of oral litoxetine, a highly Selective Serotonin Reuptake Inhibitor (SSRI) and Multiple Serotonin Agonist-Antagonist, provided by dose titration to subjects suffering from urinary incontinence.

 


Over eight weeks, the safety profile of Litoxetine will be explored together with effect measures such as frequency of incontinence episodes, change in rate of nocturia, and change in usage of incontinence pads.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree